Sort   by:  
 Page size 
0
UnknownPilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease with an implantable ultrasound device.
Not available
S-EPMC8905724 | biostudies-literature
0
UnknownPrimary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation.
Not available
S-EPMC3229657 | biostudies-literature
0
UnknownDendrimeric Poly(Epsilon-Lysine) Delivery Systems for the Enhanced Permeability of Flurbiprofen across the Blood-Brain Barrier in Alzheimer's Disease.
Not available
S-EPMC6214014 | biostudies-other
0
UnknownImbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer's Disease in a Preclinical Model: A Therapeutic Opportunity.
Not available
S-EPMC7694492 | biostudies-literature
0
UnknownComputational Prediction of the Interaction of Ivermectin with Fibrinogen.
Not available
S-EPMC10380762 | biostudies-literature
0
UnknownLenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Not available
S-EPMC11651366 | biostudies-literature
0
UnknownEvaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery.
Not available
S-EPMC4741477 | biostudies-literature
0
UnknownFirst-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
Not available
S-EPMC7255978 | biostudies-literature
0
UnknownA KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
Not available
S-EPMC3342446 | biostudies-literature
0
UnknownDHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Not available
S-EPMC8722447 | biostudies-literature
Sort   by:  
 Page size